BRISBANE, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a
biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that it has
been named an M&A Advisor Turnaround Award winner for Chapter 11 Reorganization of the Year.
KaloBios received the award in the $10 million to $25 million company size category for its work to successfully emerge from
Chapter 11 bankruptcy on June 30, 2016.
“This award highlights our ability to execute in challenging circumstances to reach our goals and ultimately transform
KaloBios,” said Cameron Durrant, MD, KaloBios chairman and CEO. “We are grateful for the recognition of our very talented team’s
efforts.”
The award was presented at M&A Advisor’s 11th Annual Distressed Investing Summit. For more information on the conference and
the award, please visit:
http://www.cvent.com/events/2017-distressed-investing-summit-featuring-11th-annual-turnaround-awards/event-summary-4a15eb768f714edd8170809430c0a745.aspx.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients
with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are
benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and
ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as chronic myelomonocytic
leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 mike.cole@mzgroup.us Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 media@kalobios.com
